Phase II Double-Blinded Placebo-Controlled Study Of Bevacizumab with or without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma

Share

Study Number:
RTOG 1122

Topic:
Recurrent Glioblastoma

Principal Investigator:
Redmond

Addtional Investigators:
Curry
Chaudhary

Ongoing:
Ongoing

Place:
UC Health

Overview:

The purpose of this study is to find out the effect of bevacizumab with or without a new investigational drug, AMG 386, on you and your tumor. Bevacizumab is a protein that works by preventing new cancer-related blood vessel formation. The U.S. Food and Drug Administration (FDA) has approved bevacizumab for the treatment of recurrent glioblastoma. However, treatment with bevacizumab alone has only modestly improved overall survival in patients with this type of brain tumor. For this reason, other drugs, such as AMG 386, are being evaluated.

You may or may not receive the investigational drug AMG 386 depending on which treatment group you are placed in. The word “investigational” means that the drug is being tested and is not approved by the FDA. This study will look at whether or not adding AMG 386 to bevacizumab is more effective in fighting your brain tumor by slowing its growth, stopping growth, or shrinking the tumor as compared to bevacizumab alone. This study will also look at the side effects of AMG 386 plus bevacizumab in you and other participants with glioblastoma. It is hoped that AMG 386 will kill tumor cells and that it may also block blood vessels that supply the tumor in your brain with nutrients and oxygen. AMG 386 has been used and is currently being used in other clinical trials treating recurrent glioblastoma and other cancers.

The first part of this study (Cohort 1) will test the safety of a combination of AMG 386 weekly and bevacizumab every 2 weeks in participants who have never received any treatments that block blood vessel formation. When the safety of this treatment is determined, the second part of this study (Cohort 2) will begin. 

In Cohort 2 you will be randomized (randomly assigned) to receive either bevacizumab plus placebo (inactive substance) or bevacizumab plus AMG 386.  You will receive bevacizumab every 2 weeks and placebo or AMG 386 once per week.

After you are finished taking bevacizumab plus AMG 386/placebo, you will have follow-up assessments 30 days after the end of treatment, then every 2 months for 1 year after the end of treatment, then every 6 months for the next year, and then annually. 

About 141 people will take part in this study with about 6 of those being local.

Qualifications:
Eligible patients must be at least 18 years old and have a brain tumor, called a glioblastoma or gliosarcoma, which has become worse after other treatment.

Contact:
Alison Kastl 513-584-0436 or kastla@ucmail.uc.edu

This entry was posted in . Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Print This Page
  • Make an Appointment: Schedule Now
  • Sign up for our newsletter!
  • Hope Stories

    • Jerry’s Story: Spinal Tumor

      Jerry's Story: Spinal Tumor On an ordinary day in February 2009, John M. Tew, MD, got one of the true surprises of his career. He was seeing patients in his Mayfield Clinic office on the University of Cincinnati medical campus when an unexpected guest...
    • Jim’s Story: Acromegaly / Pituitary Tumor

      Jim's Story: Acromegaly / Pituitary Tumor Four years later, Jim’s story just keeps getting better. Because four years after being treated for a pituitary tumor at the UC Brain Tumor Center, Jim continues to feel better and better. The size of his head has gone down....
    • Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’

      Troy’s Testimonial: ‘Out of 5 Stars, They Get 6’ Troy Sheldon has something to say, and he’d like...
    • Lynne’s Story: Brain Metastasis

      Lynne's Story: Brain MetastasisSemiretired and working part-time at a restaurant, Lynne knew something was amiss when she looked at the cash register and then struggled to make her hands produce the correct amount of change. Could she have suffered a stroke? Lynne pushed the...
    • Brian’s Story: Meningioma

      Brian's Story: Meningioma “Carefree” is the word Brian uses to describe his life back then. He was 39 years old, happily married and the father of three children under the age of 5. “Life was busy, but that felt normal,” he says, reflecting. “The only...
    • Troy’s Story: Proton Therapy for Brain Cancer

      Troy's Story: Proton Therapy for Brain Cancer Troy Witt, 65, a London, Kentucky resident and a self-proclaimed "country boy,” says he loves his family, fishing, woodworking and riding on his tractor. But all of these activities have been put on hold since spring 2016 when Witt’s...
    • Bob’s Story: Recurrent Glioblastoma

      Bob's Story: Recurrent Glioblastoma Glioblastomas come back. Sometimes sooner, sometimes later, but they always come back. “That’s the...